NEWS: We’ve announced LanzaX, a dedicated business unit for our synthetic biology platform, which we intend to spin out as a joint venture with Tharsis Capital in the coming months.
For the last 20 years, LanzaTech’s mission has been to recycle carbon with biology—and we’ve focused on developing both the biorefining hardware (i.e. commercial facilities) and the organisms needed to do that. As we sharpen the financial and operational foundation of our core biorefining platform, spinning out LanzaX means that our synthetic biology and strain engineering platform will have the necessary capital to accelerate its project pipeline, which includes high-value chemicals such as acetone and isopropanol, with a wide spanning roster of global firms, brand leaders, and universities.
Building on 15+ years of development and optimization of continuous, gas fermentation organisms, LanzaX capabilities include:
?? Leading synthetic biology platform for C1 organisms
?? Strain modeling, AI, and synthetic biology capabilities across full design-build-test-learn cycle
?? World-first biofoundry for automated strain engineering of gas fermentation organisms
?? Utilization of waste-based feedstocks
?? Commercial scale expertise
Ultimately, LanzaX’s strain innovation intends to expand the production of industrially-relevant chemicals beyond ethanol with LanzaTech’s biorefining hardware. Our vision for a circular carbon economy relies on transforming waste carbon into the building blocks for our everyday goods and materials. Expanding the portfolio of carbon recycling strains means the direct production of more molecules, more efficient supply chains, and a reduced dependence on fossil fuels.
